Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:03 PM
Ignite Modification Date: 2025-12-24 @ 1:03 PM
NCT ID: NCT00002361
Eligibility Criteria: Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Have a viral load (level of HIV in the blood) of 2500 copies/ml or greater within 45 days of study entry. * Have a CD4 cell count of 100 cells/mm3 or greater within 45 days of study entry. * Have been on an anti-HIV drug regimen containing a protease inhibitor for at least 16 weeks and initially did well on this treatment (your viral load decreased significantly) but later experienced treatment failure on this drug combination (your viral load increased significantly). * Experienced treatment failure within 24 weeks of study entry. * Are 18 years of age or older. * Agree to use effective barrier methods of birth control (such as condoms) during the study. Exclusion Criteria You will not be eligible for this study if you: * Are allergic to ritonavir or indinavir. * Have hepatitis. * Have an abnormal chest x-ray or abnormal liver function tests. * Have taken 2 protease inhibitors at the same time for 7 or more days. * Have taken non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the 2 weeks before study entry. * Have a medical condition that might make it unsafe for you to take the study drugs. * Have experienced resistance to NRTIs and no new NRTI therapy is possible. * Have taken certain medications. * Abuse alcohol or drugs. * Are pregnant or breast-feeding.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00002361
Study Brief:
Protocol Section: NCT00002361